With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Health financing and payment, results-based financing, social protection, conditional cash transfer programs, noncommunicable disease, maternal and child health
Amanda Glassman is executive vice president and senior fellow at the Center for Global Development and also serves as chief executive officer of CGD Europe. Her research focuses on priority-setting, resource allocation and value for money in global health, as well as data for development. Prior to her current position, she served as director for global health policy at the Center from 2010 to 2016, and has more than 25 years of experience working on health and social protection policy and programs in Latin America and elsewhere in the developing world.
Prior to joining CGD, Glassman was principal technical lead for health at the Inter-American Development Bank, where she led policy dialogue with member countries, designed the results-based grant program Salud Mesoamerica 2015 and served as team leader for conditional cash transfer programs such as Mexico’s Oportunidades and Colombia’s Familias en Accion. From 2005-2007, Glassman was deputy director of the Global Health Financing Initiative at Brookings and carried out policy research on aid effectiveness and domestic financing issues in the health sector in low-income countries. Before joining the Brookings Institution, Glassman designed, supervised and evaluated health and social protection loans at the Inter-American Development Bank and worked as a Population Reference Bureau Fellow at the US Agency for International Development. Glassman holds a MSc from the Harvard School of Public Health and a BA from Brown University, has published on a wide range of health and social protection finance and policy topics, and is editor and coauthor of the books What's In, What's Out: Designing Benefits for Universal Health Coverage (Center for Global Development, 2017), Millions Saved: New Cases of Proven Success in Global Health (Center for Global Development 2016), From Few to Many: A Decade of Health Insurance Expansion in Colombia (IDB and Brookings 2010), and The Health of Women in Latin America and the Caribbean (World Bank 2001).
Everyone seems to be throwing their hat into the ring in the battle against non-communicable disease (NCD), from George W. Bush to Lance Armstrong. Now it appears USAID has entered the mix as well. Despite the agency’s absence from a CGD sponsored panel discussion last week, the USAID communications department is shifting into full gear—implying that they plan to join the fight after all.
On September 20, heads of state and officials from every country in the world will meet at the United Nations to discuss the non-communicable diseases (NCD) -- heart disease, cancers, diabetes, and asthma -- that are responsible for 63 percent of global deaths annually. Contrary to popular belief, NCD do not primarily affect those of us living in wealthy countries; rather, 80 percent of NCD deaths occur in developing countries, mostly the middle-income countries.
In 9 days, the UN High Level Summit will meet to discuss the detrimental effects of noncommunicable disease (NCDs) and what can be done to mitigate them. If raising awareness was a goal, the meeting has already been a success. Media coverage on global NCD has exploded (see here, here, and here to start).
Noncommunicable diseases (NCDs) such as cancer, diabetes, respiratory and cardiovascular diseases, and mental illnesses are the leading cause of death and disability worldwide. The good news is that much of the NCD burden can be prevented through interventions that are affordable in most countries. The United States can help now by taking five low-cost or no-cost steps.
Coming your way in September, Contagion is a star-filled movie about a global bird flu outbreak complete with scary music, frequent deaths, and breakdown of public order… the usual fare.
But dramatic soundtracks aside, there are good scientific and security reasons to fear novel viruses like H5N1 and an uncoordinated, fragmented and ineffectual response. A 2010 study examining the initial response of health care institutions to H1N1 found that over half of hospitals included in the study neglected important infection prevention measures during the crisis. The New England Journal of Medicine cites that one month following the release of the H1N1 vaccine only 7 percent of high-priority adults had been vaccinated. According to the same study, nine months following the pandemic, 39 percent of survey respondents said the government response was fair or poor— with 54 percent of respondents stating that the federal government was doing a poor or very poor job of providing the country with adequate vaccine supplies.